<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">40910519</PMID><DateCompleted><Year>2025</Year><Month>09</Month><Day>05</Day></DateCompleted><DateRevised><Year>2025</Year><Month>09</Month><Day>08</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1460-2229</ISSN><JournalIssue CitedMedium="Internet"><Volume>42</Volume><Issue>5</Issue><PubDate><Year>2025</Year><Month>Aug</Month><Day>14</Day></PubDate></JournalIssue><Title>Family practice</Title><ISOAbbreviation>Fam Pract</ISOAbbreviation></Journal><ArticleTitle>Feasibility of implementing an intervention in general practice for deprescribing of glucose-lowering medication in overtreated elderly.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">cmaf064</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1093/fampra/cmaf064</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Elderly patients with Type 2 diabetes (T2D) are frequently overtreated with glucose-lowering medication.</AbstractText><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">This feasibility study evaluated the implementation of a deprescribing programme (DPP) for general practices, consisting of education, a patient selection tool, practice visits, and an expert support panel, before scaling it in a randomized controlled trial.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Quantitative evaluation included the number of patients with T2D eligible for deprescribing using medical records and study progress data. Qualitative evaluation entailed the analysis of minutes made during training, and interviews with health care providers (HCPs). The extended normalization process theory guided analysis.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">In 10 practices, 55 out of 65 eligible patients were deprescribed glucose-lowering medication, with 22 restarts. Most execution steps were perceived as the practice nurse's responsibility, whereas the general practitioner needed to approve the deprescribing. Practice nurses found the educational training, including peer-to-peer sessions and practice visits, supportive of integrating deprescribing into practice. DPP procedures and tasks not part of the regular care process were not consistently performed. The DPP was adapted to minimize study tasks for HCPs and align study procedures to existing routine procedures.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Implementation of a DPP in general practice requires education, practice visits, and alignment of DPP components to regular care.</AbstractText><CopyrightInformation>&#xa9; The Author(s) 2025. Published by Oxford University Press.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Andriessen</LastName><ForeName>Charlotte</ForeName><Initials>C</Initials><Identifier Source="ORCID">0000-0001-6862-1979</Identifier><AffiliationInfo><Affiliation>Department of General Practice, Amsterdam University Medical Center, Meibergdreef 15, 1105 AZ Amsterdam, The Netherlands.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Amsterdam Public Health Research Institute, 1105 AZ Amsterdam, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Blom</LastName><ForeName>Marieke T</ForeName><Initials>MT</Initials><AffiliationInfo><Affiliation>Department of General Practice, Amsterdam University Medical Center, Meibergdreef 15, 1105 AZ Amsterdam, The Netherlands.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Amsterdam Public Health Research Institute, 1105 AZ Amsterdam, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>van Hoek</LastName><ForeName>Beryl A C E</ForeName><Initials>BACE</Initials><AffiliationInfo><Affiliation>Department of General Practice, Amsterdam University Medical Center, Meibergdreef 15, 1105 AZ Amsterdam, The Netherlands.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Amsterdam Public Health Research Institute, 1105 AZ Amsterdam, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>de Boer</LastName><ForeName>Anna W</ForeName><Initials>AW</Initials><AffiliationInfo><Affiliation>Department of Public Health and Primary Care/Health Campus The Hague, LUMC, 2333 ZD Leiden, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Denig</LastName><ForeName>Petra</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Clinical Pharmacy and Pharmacology, University of Groningen, University Medical Center Groningen, 9700 AB Groningen, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Herings</LastName><ForeName>Ron</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>PHARMO Institute for Drug Outcomes Studies, 3528 AE Utrecht, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>de Rooij-Peek</LastName><ForeName>Angela</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Diabetesvereniging Nederland, 3833 LD Leusden, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>van Marum</LastName><ForeName>Rob J</ForeName><Initials>RJ</Initials><AffiliationInfo><Affiliation>Department of Geriatric Medicine, Jeroen Bosch Hospital, 5223 GZ 's-Hertogenbosch, The Netherlands.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Clinical Pharmacology, Jeroen Bosch Hospital, 5223 GZ 's-Hertogenbosch, The Netherlands.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Elderly Care Medicine, Amsterdam University Medical Center, 1081 HV Amsterdam, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hugtenburg</LastName><ForeName>Jacqueline G</ForeName><Initials>JG</Initials><AffiliationInfo><Affiliation>Department of Clinical Pharmacology and Pharmacy, Amsterdam University Medical Center, 1081 HV Amsterdam, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>van Raalte</LastName><ForeName>Dani&#xeb;l</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, Diabetes Center, Amsterdam University Medical Center, 1081 HV Amsterdam, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>van Bloemendaal</LastName><ForeName>Liselotte</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine-Geriatrics, Amsterdam University Medical Center, 1081 HV Amsterdam, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nijpels</LastName><ForeName>Giel</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of General Practice, Amsterdam University Medical Center, Meibergdreef 15, 1105 AZ Amsterdam, The Netherlands.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Amsterdam Public Health Research Institute, 1105 AZ Amsterdam, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Westerman</LastName><ForeName>Marjan J</ForeName><Initials>MJ</Initials><AffiliationInfo><Affiliation>Department of Epidemiology and Data Science, Amsterdam University Medical Center, 1105 AZ Amsterdam, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vos</LastName><ForeName>Rimke C</ForeName><Initials>RC</Initials><AffiliationInfo><Affiliation>Department of Public Health and Primary Care/Health Campus The Hague, LUMC, 2333 ZD Leiden, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Elders</LastName><ForeName>Petra J M</ForeName><Initials>PJM</Initials><AffiliationInfo><Affiliation>Department of General Practice, Amsterdam University Medical Center, Meibergdreef 15, 1105 AZ Amsterdam, The Netherlands.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Amsterdam Public Health Research Institute, 1105 AZ Amsterdam, The Netherlands.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>848018102</GrantID><Agency>ZonMW Grant Goed Gebruik Geneesmiddelen</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Fam Pract</MedlineTA><NlmUniqueID>8500875</NlmUniqueID><ISSNLinking>0263-2136</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007004">Hypoglycemic Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000069340" MajorTopicYN="Y">Deprescriptions</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003924" MajorTopicYN="Y">Diabetes Mellitus, Type 2</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005240" MajorTopicYN="N">Feasibility Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D058006" MajorTopicYN="Y">General Practice</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007004" MajorTopicYN="Y">Hypoglycemic Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">elderly</Keyword><Keyword MajorTopicYN="N">general practice</Keyword><Keyword MajorTopicYN="N">hypoglycaemia</Keyword><Keyword MajorTopicYN="N">implementation</Keyword><Keyword MajorTopicYN="N">quality improvement</Keyword><Keyword MajorTopicYN="N">type 2 diabetes</Keyword></KeywordList><CoiStatement>Conflict of interest statement: None declared</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>9</Month><Day>5</Day><Hour>12</Hour><Minute>40</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>9</Month><Day>5</Day><Hour>12</Hour><Minute>39</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>9</Month><Day>5</Day><Hour>7</Hour><Minute>13</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2025</Year><Month>8</Month><Day>26</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40910519</ArticleId><ArticleId IdType="pmc">PMC12411905</ArticleId><ArticleId IdType="doi">10.1093/fampra/cmaf064</ArticleId><ArticleId IdType="pii">8248370</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>
Ineen . <i>Transparante Ketenzorg Rapportage. Zorggroepen Diabetes mellitus, VRM, COPD en Astma. Spiegel voor het verbeteren van chronische zorg</i> [Internet], 2019. https://ineen.nl/wp-content/uploads/2020/02/InEen-Rapport-Transparante-Ketenzorg-2018.pdf</Citation></Reference><Reference><Citation>Hart HE, Rutten GE, Bontje KNet al. Overtreatment of older patients with type 2 diabetes mellitus in primary care. Diabetes Obes Metab 2018;20:1066&#x2013;9. 10.1111/dom.13174</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/dom.13174</ArticleId><ArticleId IdType="pubmed">29193555</ArticleId></ArticleIdList></Reference><Reference><Citation>Bramlage P, Gitt AK, Binz Cet al. Oral antidiabetic treatment in type-2 diabetes in the elderly: balancing the need for glucose control and the risk of hypoglycemia. Cardiovasc Diabetol 2012;11:1&#x2013;9. 10.1186/1475-2840-11-122</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1475-2840-11-122</ArticleId><ArticleId IdType="pmc">PMC3508810</ArticleId><ArticleId IdType="pubmed">23039216</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller ME, Williamson JD, Gerstein HCet al. Effects of randomization to intensive glucose control on adverse events, cardiovascular disease, and mortality in older versus younger adults in the ACCORD trial. Diabetes Care 2014;37:634&#x2013;43. 10.2337/dc13-1545</Citation><ArticleIdList><ArticleId IdType="doi">10.2337/dc13-1545</ArticleId><ArticleId IdType="pmc">PMC3931381</ArticleId><ArticleId IdType="pubmed">24170759</ArticleId></ArticleIdList></Reference><Reference><Citation>Zoungas S, Patel A, Chalmers Jet al. Severe hypoglycemia and risks of vascular events and death. N Engl J Med 2010;363:1410&#x2013;8. 10.1056/NEJMoa1003795</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1003795</ArticleId><ArticleId IdType="pubmed">20925543</ArticleId></ArticleIdList></Reference><Reference><Citation>Hambling C, Seidu S, Davies Met al. Older people with type 2 diabetes, including those with chronic kidney disease or dementia, are commonly overtreated with sulfonylurea or insulin therapies. Diabet Med 2017;34:1219&#x2013;27. 10.1111/dme.13380</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/dme.13380</ArticleId><ArticleId IdType="pubmed">28498634</ArticleId></ArticleIdList></Reference><Reference><Citation>Hope SV, Taylor PJ, Shields BMet al. Are we missing hypoglycaemia? Elderly patients with insulin-treated diabetes present to primary care frequently with non-specific symptoms associated with hypoglycaemia. Prim Care Diabetes 2018;12:139&#x2013;46. 10.1016/j.pcd.2017.08.004</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.pcd.2017.08.004</ArticleId><ArticleId IdType="pmc">PMC5857285</ArticleId><ArticleId IdType="pubmed">28918198</ArticleId></ArticleIdList></Reference><Reference><Citation>Pawaskar M, Iglay K, Witt EAet al. Impact of the severity of hypoglycemia on health-related quality of life, productivity, resource use, and costs among US patients with type 2 diabetes. J Diabetes Complications 2018;32:451&#x2013;7. 10.1016/j.jdiacomp.2018.01.012</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jdiacomp.2018.01.012</ArticleId><ArticleId IdType="pubmed">29496365</ArticleId></ArticleIdList></Reference><Reference><Citation>Sturkenboom M, Vanrolleghem A, Van den Bemt Pet al. Vervolgonderzoek medicatieveiligheid: eindrapport. Rotterdam/Utrecht/Nijmegen: Erasmus MC, Nivel, Radboud UMC, PHARMO, 2017.</Citation></Reference><Reference><Citation>Barents E, Bilo H, Bouma Met al. NHG-standaard diabetes mellitus type 2 (M01). Versie 2018;5:3.</Citation></Reference><Reference><Citation>
NHG &amp; NVKG . <i>Guideline on reducing and stopping of medication: knowledge documents blood glucose-lowering medication, blood pressure-lowering medication, and statins [richtlijnmodule minderen en stoppen van medicatie: kennisdocumenten bloedglucoseverlagende middelen, bloeddrukverlagende middelen, statines; in Dutch]</i> [Internet], 2020. https://richtlijnendatabase.nl/richtlijn/polyfarmacie_bij_ouderen/minderen_en_stoppen_van_medicatie.html (6 September 2024, date last accessed).</Citation></Reference><Reference><Citation>Turner JP, Newport K, McEvoy AMet al. Strategies to guide the successful implementation of deprescribing in community practice: lessons learned from the front line. Can Pharm J (Ott) 2024;157:133&#x2013;42. 10.1177/17151635241240737</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/17151635241240737</ArticleId><ArticleId IdType="pmc">PMC11086729</ArticleId><ArticleId IdType="pubmed">38737354</ArticleId></ArticleIdList></Reference><Reference><Citation>Abou J, Crutzen S, Tromp Vet al. Barriers and enablers of healthcare providers to deprescribe cardiometabolic medication in older patients: a focus group study. Drugs Aging 2022;39:209&#x2013;21. 10.1007/s40266-021-00918-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40266-021-00918-7</ArticleId><ArticleId IdType="pmc">PMC8934783</ArticleId><ArticleId IdType="pubmed">35187614</ArticleId></ArticleIdList></Reference><Reference><Citation>Doherty AJ, Boland P, Reed Jet al. Barriers and facilitators to deprescribing in primary care: a systematic review. BJGP Open 2020;4. 10.3399/bjgpopen20X101096</Citation><ArticleIdList><ArticleId IdType="doi">10.3399/bjgpopen20X101096</ArticleId><ArticleId IdType="pmc">PMC7465575</ArticleId><ArticleId IdType="pubmed">32723784</ArticleId></ArticleIdList></Reference><Reference><Citation>Mellot M, Jawal L, Morel Tet al. Barriers and enablers for deprescribing glucose-lowering treatment in older adults: a systematic review. J Am Med Dir Assoc 2024;25:439&#x2013;47.e18. 10.1016/j.jamda.2023.11.025</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jamda.2023.11.025</ArticleId><ArticleId IdType="pubmed">38237904</ArticleId></ArticleIdList></Reference><Reference><Citation>Oktora M, Kerr K, Hak Eet al. Rates, determinants and success of implementing deprescribing in people with type 2 diabetes: a scoping review. Diabet Med 2021;38:e14408. 10.1111/dme.14408</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/dme.14408</ArticleId><ArticleId IdType="pmc">PMC7891362</ArticleId><ArticleId IdType="pubmed">32969063</ArticleId></ArticleIdList></Reference><Reference><Citation>Goodman D, Ogrinc G, Davies Let al. Explanation and elaboration of the SQUIRE (Standards for Quality Improvement Reporting Excellence) guidelines, v. 2.0: examples of SQUIRE elements in the healthcare improvement literature. BMJ Qual Saf 2016;25:e7. 10.1136/bmjqs-2015-004480</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmjqs-2015-004480</ArticleId><ArticleId IdType="pmc">PMC5256235</ArticleId><ArticleId IdType="pubmed">27076505</ArticleId></ArticleIdList></Reference><Reference><Citation>
Nederlands Huisartsen Genootschap (NHG), Nederlandse Vereniging voor Klinische Geriatrie (NVKG) . <i>Module Minderen en stoppen van medicatie Onderdeel van de multidisciplinaire richtlijn Polyfarmacie bij ouderen</i>. Utrecht: MDR Polyfarmacie, 2020.</Citation></Reference><Reference><Citation>Thompson AG. The meaning of patient involvement and participation in health care consultations: a taxonomy. Soc Sci Med 2007;64:1297&#x2013;310. 10.1016/j.socscimed.2006.11.002</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.socscimed.2006.11.002</ArticleId><ArticleId IdType="pubmed">17174016</ArticleId></ArticleIdList></Reference><Reference><Citation>May C. Towards a general theory of implementation. Implement Sci 2013;8:1&#x2013;14. 10.1186/1748-5908-8-18</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1748-5908-8-18</ArticleId><ArticleId IdType="pmc">PMC3602092</ArticleId><ArticleId IdType="pubmed">23406398</ArticleId></ArticleIdList></Reference><Reference><Citation>Braun V, Clarke V. Using thematic analysis in psychology. Qual Res Psychol 2006;3:77&#x2013;101. 10.1191/1478088706qp063oa</Citation><ArticleIdList><ArticleId IdType="doi">10.1191/1478088706qp063oa</ArticleId></ArticleIdList></Reference><Reference><Citation>Houweling S, Kleefstra N, Van Hateren Ket al. Diabetes specialist nurse as main care provider for patients with type 2 diabetes. Neth J Med 2009;67:279&#x2013;84.</Citation><ArticleIdList><ArticleId IdType="pubmed">19687522</ArticleId></ArticleIdList></Reference><Reference><Citation>Vrijhoef H, Diederiks J, Spreeuwenberg Cet al. The nurse specialist as main care-provider for patients with type 2 diabetes in a primary care setting: effects on patient outcomes. Int J Nurs Stud 2002;39:441&#x2013;51. 10.1016/S0020-7489(01)00046-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0020-7489(01)00046-3</ArticleId><ArticleId IdType="pubmed">11909620</ArticleId></ArticleIdList></Reference><Reference><Citation>Bellary S, Kyrou I, Brown JEet al. Type 2 diabetes mellitus in older adults: clinical considerations and management. Nat Rev Endocrinol 2021;17:534&#x2013;48. 10.1038/s41574-021-00512-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41574-021-00512-2</ArticleId><ArticleId IdType="pubmed">34172940</ArticleId></ArticleIdList></Reference><Reference><Citation>Baas G, Crutzen S, Smits Set al. Process evaluation of a pharmacist-led intervention aimed at deprescribing and appropriate use of cardiometabolic medication among adult people with type 2 diabetes. Basic Clin Pharmacol Toxicol 2024;134:83&#x2013;96. 10.1111/bcpt.13931</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/bcpt.13931</ArticleId><ArticleId IdType="pubmed">37563775</ArticleId></ArticleIdList></Reference><Reference><Citation>Crutzen S, Baas G, Denig Pet al. Pharmacist-led intervention aimed at deprescribing and appropriate use of cardiometabolic medication among people with type 2 diabetes. Res Social Adm Pharm 2023;19:783&#x2013;92. 10.1016/j.sapharm.2022.11.009</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.sapharm.2022.11.009</ArticleId><ArticleId IdType="pubmed">36740525</ArticleId></ArticleIdList></Reference><Reference><Citation>Abou J, Elders PJ, Huijts Det al. Pharmacist-led deprescribing of cardiovascular and diabetes medication within a clinical medication review: the LeMON study (Less Medicines in Older Patients in the Netherlands), a cluster randomized controlled trial. Int J Clin Pharm 2025;47:717&#x2013;25. 10.1007/s11096-025-01863-w</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11096-025-01863-w</ArticleId><ArticleId IdType="pmc">PMC12125148</ArticleId><ArticleId IdType="pubmed">39847313</ArticleId></ArticleIdList></Reference><Reference><Citation>Stuijt PJ, Heringa M, van Dijk Let al. Effects of a multicomponent communication training to involve older people in decisions to DEPRESCRIBE cardiometabolic medication in primary care (CO-DEPRESCRIBE): protocol for a cluster randomized controlled trial with embedded process and economic evaluation. BMC Prim Care 2024;25:210. 10.1186/s12875-024-02465-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12875-024-02465-7</ArticleId><ArticleId IdType="pmc">PMC11165805</ArticleId><ArticleId IdType="pubmed">38862899</ArticleId></ArticleIdList></Reference><Reference><Citation>van der Horst DE, Garvelink MM, Bos WJWet al. For which decisions is shared decision making considered appropriate?&#x2013;A systematic review. Patient Educ Couns 2023;106:3&#x2013;16. 10.1016/j.pec.2022.09.015</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.pec.2022.09.015</ArticleId><ArticleId IdType="pubmed">36220675</ArticleId></ArticleIdList></Reference><Reference><Citation>Walsh K, Kwan D, Marr Pet al. Deprescribing in a family health team: a study of chronic proton pump inhibitor use. J Prim Health Care 2016;8:164&#x2013;71. 10.1071/HC15946</Citation><ArticleIdList><ArticleId IdType="doi">10.1071/HC15946</ArticleId><ArticleId IdType="pubmed">27477559</ArticleId></ArticleIdList></Reference><Reference><Citation>Houweling B, Bakker S, Hart Bet al. Langerhans beslisbomen diabetes mellitus type 2. Zeist: Stichting Langerhans, 2022&#x2013;2023.</Citation></Reference><Reference><Citation>Hogervorst S, Vervloet M, Adriaanse MCet al. Scalability of effective adherence interventions for patients using cardiovascular disease medication: a realist synthesis-inspired systematic review. Br J Clin Pharmacol 2023;89:1996&#x2013;2019. 10.1111/bcp.15418</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/bcp.15418</ArticleId><ArticleId IdType="pubmed">35617955</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>